These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21864512)

  • 1. Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs.
    Miller CP; Manton CA; Hale R; Debose L; Macherla VR; Potts BC; Palladino MA; Chandra J
    Chem Biol Interact; 2011 Oct; 194(1):58-68. PubMed ID: 21864512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
    Miller CP; Ban K; Dujka ME; McConkey DJ; Munsell M; Palladino M; Chandra J
    Blood; 2007 Jul; 110(1):267-77. PubMed ID: 17356134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
    Miller CP; Rudra S; Keating MJ; Wierda WG; Palladino M; Chandra J
    Blood; 2009 Apr; 113(18):4289-99. PubMed ID: 19182209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.
    Ruiz S; Krupnik Y; Keating M; Chandra J; Palladino M; McConkey D
    Mol Cancer Ther; 2006 Jul; 5(7):1836-43. PubMed ID: 16891470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist.
    Boccellato C; Kolbe E; Peters N; Juric V; Fullstone G; Verreault M; Idbaih A; Lamfers MLM; Murphy BM; Rehm M
    Cell Death Dis; 2021 Jun; 12(7):647. PubMed ID: 34168123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
    Fuchs O; Provaznikova D; Marinov I; Kuzelova K; Spicka I
    Cardiovasc Hematol Disord Drug Targets; 2009 Mar; 9(1):62-77. PubMed ID: 19275578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of salinosporamide A and its analogs as 20S proteasome inhibitors and SAR summarization.
    Ma Y; Qu L; Liu Z; Zhang L; Yang Z; Zhang L
    Curr Top Med Chem; 2011 Dec; 11(23):2906-22. PubMed ID: 21824108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
    Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
    Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs.
    Obaidat A; Weiss J; Wahlgren B; Manam RR; Macherla VR; McArthur K; Chao TH; Palladino MA; Lloyd GK; Potts BC; Enna SJ; Neuteboom ST; Hagenbuch B
    J Pharmacol Exp Ther; 2011 May; 337(2):479-86. PubMed ID: 21303921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marizomib (Salinosporamide A) Promotes Apoptosis in A375 and G361 Melanoma Cancer Cells.
    Piskorz WM; Krętowski R; Cechowska-Pasko M
    Mar Drugs; 2024 Jul; 22(7):. PubMed ID: 39057424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
    Corrales-Medina FF; Manton CA; Orlowski RZ; Chandra J
    Leuk Res; 2015 Mar; 39(3):371-9. PubMed ID: 25612941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
    Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
    J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
    Di K; Lloyd GK; Abraham V; MacLaren A; Burrows FJ; Desjardins A; Trikha M; Bota DA
    Neuro Oncol; 2016 Jun; 18(6):840-8. PubMed ID: 26681765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
    Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
    Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
    Raninga PV; Lee A; Sinha D; Dong LF; Datta KK; Lu X; Kalita-de Croft P; Dutt M; Hill M; Pouliot N; Gowda H; Kalimutho M; Neuzil J; Khanna KK
    Theranostics; 2020; 10(12):5259-5275. PubMed ID: 32373211
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
    Singh AV; Palladino MA; Lloyd GK; Potts BC; Chauhan D; Anderson KC
    Br J Haematol; 2010 May; 149(4):550-9. PubMed ID: 20331453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome structure, function, and lessons learned from beta-lactone inhibitors.
    Groll M; Potts BC
    Curr Top Med Chem; 2011 Dec; 11(23):2850-78. PubMed ID: 21824111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marizomib, a potent second generation proteasome inhibitor from natural origin.
    Ma L; Diao A
    Anticancer Agents Med Chem; 2015; 15(3):298-306. PubMed ID: 25403165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
    Yu C; Rahmani M; Dent P; Grant S
    Exp Cell Res; 2004 May; 295(2):555-66. PubMed ID: 15093752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib.
    Williamson MJ; Blank JL; Bruzzese FJ; Cao Y; Daniels JS; Dick LR; Labutti J; Mazzola AM; Patil AD; Reimer CL; Solomon MS; Stirling M; Tian Y; Tsu CA; Weatherhead GS; Zhang JX; Rolfe M
    Mol Cancer Ther; 2006 Dec; 5(12):3052-61. PubMed ID: 17172407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.